MedTrace Logo

Effects of Ecopipam or Placebo in Adults With Stuttering (Speak Freely)

NCT04492956 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2022-04-28

No results posted yet for this study

Summary

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 exploratory study in adult subjects with childhood onset fluency disorder.

Conditions

  • Childhood-Onset Fluency Disorder (Stuttering)

Interventions

DRUG

Ecopipam

Oral tablet

DRUG

Placebo

Oral tablet

Sponsors & Collaborators

  • University of California, Riverside

    collaborator OTHER

  • Premier Research Group plc

    collaborator UNKNOWN

  • Emalex Biosciences Inc.

    lead INDUSTRY

Principal Investigators

  • Atul R Mahableshwarkar, MD, DFAPA · Emalex Biosciences Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-02
Primary Completion
2022-03-07
Completion
2022-04-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04492956 on ClinicalTrials.gov